论文部分内容阅读
应用胰岛素、胰岛素促泌剂、二甲双胍、西格列汀治疗欠佳的T2DM患者28例,在原治疗基础上联合应用利拉鲁肽治疗16周。治疗前后检测糖化血红蛋白(HbA1c)、空腹血糖(FPG),糖负荷后2小时血糖(2hPG)、空腹C肽(FC-P)、糖负荷后2小时C肽(2hC-P)、血脂、体重、体重指数(BMI)、腰围(WC)、收缩压(SBP)、舒张压(DBP)及肝肾功能、心电图等。并记录低血糖等不良反应相关指标变化。治疗后多项指标较治疗前基线值下降,血脂异常有所改变,血清FC-P、2hc-P明显升高、低血糖发生率显著减少均有统计学意义(P<0.05、P<0.01)。利拉鲁肽联合胰岛素、胰岛素促泌剂、二甲双胍对治疗欠佳的2型糖尿病患者具有良好的控制血糖、减轻体重、减少低血糖风险和改善胰岛功能且有较好的安全性。
28 cases of T2DM with poor insulin treatment, insulin secretagogues, metformin and sitagliptin were treated with liraglutide for 16 weeks on the basis of the original treatment. Before and after treatment, HbA1c, FPG, 2hPG, FC-P, 2h C-P, blood lipid, , Body mass index (BMI), waist circumference (WC), systolic blood pressure (SBP), diastolic blood pressure (DBP) and liver and kidney function, ECG and so on. And record changes in indicators related to adverse reactions such as hypoglycemia. After treatment a number of indicators than before treatment baseline value decreased, dyslipidemia changed, serum FC-P, 2hc-P was significantly increased, a significant reduction in the incidence of hypoglycemia were statistically significant (P <0.05, P <0.01) . Liraglutide in combination with insulin, insulin secretagogues and metformin have good control of blood sugar, weight loss, risk of hypoglycaemia and improvement of pancreatic islet function in patients with poorly-modeled type 2 diabetes and has good safety.